Brought to you by 
Lummy licenses cancer immunotherapy rights from Argos; Deal ends
27 Jul 2022
Executive Summary
Argos Therapeutics Inc. granted Chongqing Lummy Pharmaceutical Co. Ltd. and its Lummy (Hong Kong) Co. Ltd. subsidiary exclusive rights to develop, manufacture, and sell its Phase III renal cell carcinoma candidate AGS003 in China, Hong Kong, Taiwan, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lummy licenses cancer immunotherapy rights from Argos; Deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice